Interleukin-22 Promotes Aerobic Glycolysis Associated with Tumor Progression Via Targeting Hexokinase-2 in Human Colon Cancer Cells

Overview

Journal Oncotarget

Specialty Oncology

Date 2017 Apr 28

PMID 28445985

Citations 11

Authors

Yulin Liu

Fan Xiang

Yongming Huang

Liang Shi

Chaojie Hu

Yiming Yang

Di Wang

Nan He

Kaixiong Tao

Ke Wu

Guobin Wang

Affiliations

Soon will be listed here.

Abstract

Interleukin-22 has been explored extensively in human cancer, but its functions and underlying mechanisms are incompletely understood. Here, we show that aberrant interleukin-22 expression facilitates aerobic glycolysis in colon cancer cells. Elevated interleukin-22 mRNA expression was observed and positively correlated with hexokinase-2 in colon cancer tissues. In vitro, interleukin-22 enhanced glucose consumption and lactate production via targeting hexokinase-2 in colon cancer cells. Moreover, the transcriptional factor c-Myc and signal transducer and activator of transcription 3 were involved in interleukin-22-induced up-regulation of hexokinase-2. We further demonstrated that hexokinase-2 partly accounted for interleukin-22-mediated cellular proliferation in DLD-1 cells. In vivo, our data demonstrated that interleukin-22 significantly promoted tumor growth along with elevated expression of c-Myc and hexokinase-2 in mice. In summary, our findings provide a new perspective on the pro-inflammatory cytokine interleukin-22 in promoting aerobic glycolysis associated with tumor progression in human colon cancer cells.

Citing Articles

IL-22 regulates MASTL expression in intestinal epithelial cells.

Pravoverov K, Fatima I, Barman S, Juhling F, Primeaux M, Baumert T Am J Physiol Gastrointest Liver Physiol. 2024; 327(2):G123-G139.

PMID: 38771154 PMC: 11687961. DOI: 10.1152/ajpgi.00260.2023.

Intestinal IL-22RA1 signaling regulates intrinsic and systemic lipid and glucose metabolism to alleviate obesity-associated disorders.

Gaudino S, Singh A, Huang H, Padiadpu J, Jean-Pierre M, Kempen C Nat Commun. 2024; 15(1):1597.

PMID: 38383607 PMC: 10881576. DOI: 10.1038/s41467-024-45568-6.

STAT proteins in cancer: orchestration of metabolism.

Li Y, Zhang C, Martincuks A, Herrmann A, Yu H Nat Rev Cancer. 2023; 23(3):115-134.

PMID: 36596870 DOI: 10.1038/s41568-022-00537-3.

Enhancing an Oxidative "Trojan Horse" Action of Vitamin C with Arsenic Trioxide for Effective Suppression of KRAS-Mutant Cancers: A Promising Path at the Bedside.

Burska A, Ilyassova B, Dildabek A, Khamijan M, Begimbetova D, Molnar F Cells. 2022; 11(21).

PMID: 36359850 PMC: 9657932. DOI: 10.3390/cells11213454.

3-Bromopyruvic acid regulates glucose metabolism by targeting the c-Myc/TXNIP axis and induces mitochondria-mediated apoptosis in TNBC cells.

Li J, Pan J, Liu Y, Luo X, Yang C, Xiao W Exp Ther Med. 2022; 24(2):520.

PMID: 35837063 PMC: 9257941. DOI: 10.3892/etm.2022.11447.

References

Hasnain S, Borg D, Harcourt B, Tong H, Sheng Y, Ng C . Glycemic control in diabetes is restored by therapeutic manipulation of cytokines that regulate beta cell stress. Nat Med. 2014; 20(12):1417-26. DOI: 10.1038/nm.3705. View

Wu T, Wang Z, Liu Y, Mei Z, Wang G, Liang Z . Interleukin 22 protects colorectal cancer cells from chemotherapy by activating the STAT3 pathway and inducing autocrine expression of interleukin 8. Clin Immunol. 2014; 154(2):116-26. DOI: 10.1016/j.clim.2014.07.005. View

Ge X, Chen C, Hui X, Wang Y, Lam K, Xu A . Fibroblast growth factor 21 induces glucose transporter-1 expression through activation of the serum response factor/Ets-like protein-1 in adipocytes. J Biol Chem. 2011; 286(40):34533-41. PMC: 3186365. DOI: 10.1074/jbc.M111.248591. View

Lejeune D, Dumoutier L, Constantinescu S, Kruijer W, Schuringa J, Renauld J . Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line. Pathways that are shared with and distinct from IL-10. J Biol Chem. 2002; 277(37):33676-82. DOI: 10.1074/jbc.M204204200. View

Kiuchi N, Nakajima K, Ichiba M, Fukada T, Narimatsu M, Mizuno K . STAT3 is required for the gp130-mediated full activation of the c-myc gene. J Exp Med. 1999; 189(1):63-73. PMC: 1887683. DOI: 10.1084/jem.189.1.63. View

Kim J, Zeller K, Wang Y, Jegga A, Aronow B, ODonnell K . Evaluation of myc E-box phylogenetic footprints in glycolytic genes by chromatin immunoprecipitation assays. Mol Cell Biol. 2004; 24(13):5923-36. PMC: 480875. DOI: 10.1128/MCB.24.13.5923-5936.2004. View

Wolk K, Kunz S, Witte E, Friedrich M, Asadullah K, Sabat R . IL-22 increases the innate immunity of tissues. Immunity. 2004; 21(2):241-54. DOI: 10.1016/j.immuni.2004.07.007. View

Czabotar P, Lessene G, Strasser A, Adams J . Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol. 2013; 15(1):49-63. DOI: 10.1038/nrm3722. View

Volpe E, Servant N, Zollinger R, Bogiatzi S, Hupe P, Barillot E . A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat Immunol. 2008; 9(6):650-7. DOI: 10.1038/ni.1613. View

10.

Jiang R, Tan Z, Deng L, Chen Y, Xia Y, Gao Y . Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3. Hepatology. 2011; 54(3):900-9. DOI: 10.1002/hep.24486. View

11.

Li J, Liu T, Zhao L, Chen W, Hou H, Ye Z . Ginsenoside 20(S)‑Rg3 inhibits the Warburg effect through STAT3 pathways in ovarian cancer cells. Int J Oncol. 2014; 46(2):775-81. DOI: 10.3892/ijo.2014.2767. View

12.

Annibaldi A, Widmann C . Glucose metabolism in cancer cells. Curr Opin Clin Nutr Metab Care. 2010; 13(4):466-70. DOI: 10.1097/MCO.0b013e32833a5577. View

13.

Wang X, Ota N, Manzanillo P, Kates L, Zavala-Solorio J, Eidenschenk C . Interleukin-22 alleviates metabolic disorders and restores mucosal immunity in diabetes. Nature. 2014; 514(7521):237-41. DOI: 10.1038/nature13564. View

14.

Kryczek I, Lin Y, Nagarsheth N, Peng D, Zhao L, Zhao E . IL-22(+)CD4(+) T cells promote colorectal cancer stemness via STAT3 transcription factor activation and induction of the methyltransferase DOT1L. Immunity. 2014; 40(5):772-784. PMC: 4032366. DOI: 10.1016/j.immuni.2014.03.010. View

15.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

16.

McLeod H, Murray G . Tumour markers of prognosis in colorectal cancer. Br J Cancer. 1999; 79(2):191-203. PMC: 2362193. DOI: 10.1038/sj.bjc.6690033. View

17.

Duhen T, Geiger R, Jarrossay D, Lanzavecchia A, Sallusto F . Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol. 2009; 10(8):857-63. DOI: 10.1038/ni.1767. View

18.

Pestka S, Krause C, Sarkar D, Walter M, Shi Y, Fisher P . Interleukin-10 and related cytokines and receptors. Annu Rev Immunol. 2004; 22:929-79. DOI: 10.1146/annurev.immunol.22.012703.104622. View

19.

Wang Y, Yun Y, Wu B, Wen L, Wen M, Yang H . FOXM1 promotes reprogramming of glucose metabolism in epithelial ovarian cancer cells via activation of GLUT1 and HK2 transcription. Oncotarget. 2016; 7(30):47985-47997. PMC: 5216994. DOI: 10.18632/oncotarget.10103. View

20.

Jiang R, Wang H, Deng L, Hou J, Shi R, Yao M . IL-22 is related to development of human colon cancer by activation of STAT3. BMC Cancer. 2013; 13:59. PMC: 3607898. DOI: 10.1186/1471-2407-13-59. View